ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 1.03TCr 883.57Cr 826.59Cr 755.71Cr 1.43TCr 99TCr 1.44TCr 9.78TCr 3.8TCr 50TCr 3.87TCr 3.79TCr 1,64000Cr | P/E 2026 * |
-17x | P/E 2027 * | -32.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1.02TCr 874.75Cr 818.33Cr 748.16Cr 1.41TCr 98TCr 1.43TCr 9.68TCr 3.77TCr 49TCr 3.83TCr 3.75TCr 1,62400Cr | EV / Sales 2026 * |
11.2x | EV / Sales 2027 * | 7.39x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 1.03TCr | |
| +0.85% | +4.98% | +3.70% | +25.50% | 5.12TCr | |
| +1.01% | -0.20% | +471.68% | +564.93% | 4.53TCr | |
| +0.16% | +7.88% | +36.14% | +20.76% | 4.28TCr | |
| -0.66% | +2.61% | +18.59% | +87.04% | 4.23TCr | |
| +0.88% | -3.48% | +17.20% | +53.83% | 3.22TCr | |
| -0.12% | +3.84% | +33.73% | +145.25% | 1.73TCr | |
| -0.53% | +1.84% | - | - | 1.65TCr | |
| +0.27% | +5.46% | +10.07% | +31.51% | 1.48TCr | |
| +1.15% | +4.17% | +84.49% | +50.33% | 1.43TCr | |
| Average | +0.43% | +3.23% | +84.45% | +122.39% | 3.08TCr | |
| Weighted average by Cap. | +0.42% | +3.07% | +101.46% | +141.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 91Cr 78Cr 73Cr 67Cr 126.34Cr 8.75TCr 127.68Cr 866.54Cr 336.94Cr 4.39TCr 342.95Cr 335.53Cr 15TCr | 140.21Cr 120.16Cr 112.41Cr 102.77Cr 193.94Cr 13TCr 196Cr 1.33TCr 517.23Cr 6.74TCr 526.45Cr 515.05Cr 22TCr |
| Net income | -60Cr -52Cr -48Cr -44Cr -83Cr -5.77TCr -84Cr -571.52Cr -222.23Cr -2.9TCr -226.19Cr -221.3Cr -9.58TCr | -33Cr -28Cr -26Cr -24Cr -45Cr -3.12TCr -46Cr -309.14Cr -120.21Cr -1.57TCr -122.35Cr -119.7Cr -5.18TCr |
| Net Debt | -10Cr -8.82Cr -8.25Cr -7.55Cr -14Cr -985.91Cr -14Cr -98Cr -38Cr -495.07Cr -39Cr -38Cr -1.64TCr | 5.75Cr 4.92Cr 4.61Cr 4.21Cr 7.95Cr 550.14Cr 8.03Cr 55Cr 21Cr 276.25Cr 22Cr 21Cr 914Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
